Ken Griffin’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $72.5M | Sell |
1,099,858
-63,079
| -5% | -$4.01M | 0.01% | 1052 |
|
|
2025
Q4 | $73.9M | Sell |
1,162,937
-223,128
| -16% | -$13.9M | 0.01% | 1083 |
|
|
2025
Q3 | $76.2M | Buy |
1,386,065
+87,456
| +7% | +$3.6M | 0.01% | 1039 |
|
|
2025
Q2 | $42.9M | Buy |
1,298,609
+148,095
| +13% | +$5.15M | 0.01% | 1356 |
|
|
2025
Q1 | $46.2M | Sell |
1,150,514
-221,131
| -16% | -$10.2M | 0.01% | 1216 |
|
|
2024
Q4 | $64.5M | Buy |
1,371,645
+434,454
| +46% | +$22.6M | 0.01% | 1060 |
|
|
2024
Q3 | $49.5M | Buy |
937,191
+78,218
| +9% | +$4.36M | 0.01% | 1220 |
|
|
2024
Q2 | $46.5M | Buy |
858,973
+298,071
| +53% | +$18M | 0.01% | 1207 |
|
|
2024
Q1 | $39.3M | Buy |
560,902
+288,309
| +106% | +$22.3M | 0.01% | 1408 |
|
|
2023
Q4 | $22.8M | Sell |
272,593
-959,231
| -78% | -$34.7M | ﹤0.01% | 1886 |
|
|
2023
Q3 | $36.3M | Buy |
1,231,824
+331,835
| +37% | +$11.1M | 0.01% | 1345 |
|
|
2023
Q2 | $29.4M | Buy |
+899,989
| New | +$33.3M | 0.01% | 1494 |
|
|
2023
Q1 | – | Sell |
-80,263
| Closed | -$3.27M | – | 14837 |
|
|
2022
Q4 | $3.68M | Sell |
80,263
-417,392
| -84% | -$18M | ﹤0.01% | 4398 |
|
|
2022
Q3 | $24.1M | Sell |
497,655
-4,145,172
| -89% | -$200M | 0.01% | 1690 |
|
|
2022
Q2 | $182M | Buy |
4,642,827
+4,370,177
| +1,603% | +$176M | 0.05% | 303 |
|
|
2022
Q1 | $10M | Buy |
272,650
+240,717
| +754% | +$8.55M | ﹤0.01% | 2956 |
|
|
2021
Q4 | $1.46M | Sell |
31,933
-261,674
| -89% | -$10.1M | ﹤0.01% | 6952 |
|
|
2021
Q3 | $10.5M | Buy |
293,607
+206,533
| +237% | +$6.08M | ﹤0.01% | 2994 |
|
|
2021
Q2 | $1.72M | Sell |
87,074
-234,642
| -73% | -$5.51M | ﹤0.01% | 6967 |
|
|
2021
Q1 | $7.48M | Buy |
321,716
+221,545
| +221% | +$4.73M | ﹤0.01% | 3453 |
|
|
2020
Q4 | $2.08M | Sell |
100,171
-1,201,778
| -92% | -$22M | ﹤0.01% | 5280 |
|
|
2020
Q3 | $28.2M | Buy |
1,301,949
+622,924
| +92% | +$14.6M | 0.01% | 1281 |
|
|
2020
Q2 | $16M | Sell |
679,025
-485,691
| -42% | -$9.11M | 0.01% | 1703 |
|
|
2020
Q1 | $13.7M | Buy |
1,164,716
+1,121,024
| +2,566% | +$14.3M | 0.01% | 1551 |
|
|
2019
Q4 | $464K | Sell |
43,692
-10,806
| -20% | -$111K | ﹤0.01% | 6935 |
|
|
2019
Q3 | $620K | Buy |
54,498
+2,959
| +6% | +$37.1K | ﹤0.01% | 6392 |
|
|
2019
Q2 | $580K | Sell |
51,539
-95,090
| -65% | -$917K | ﹤0.01% | 6597 |
|
|
2019
Q1 | $1.19M | Sell |
146,629
-73,824
| -33% | -$543K | ﹤0.01% | 5280 |
|
|
2018
Q4 | $1.39M | Buy |
+220,453
| New | +$1.62M | ﹤0.01% | 4751 |
|
|
2018
Q3 | – | Sell |
-64,601
| Closed | -$518K | – | 9272 |
|
|
2018
Q2 | $536K | Sell |
64,601
-207,868
| -76% | -$1.73M | ﹤0.01% | 6257 |
|
|
2018
Q1 | $1.96M | Sell |
272,469
-149,708
| -35% | -$1.28M | ﹤0.01% | 3766 |
|
|
2017
Q4 | $3.44M | Sell |
422,177
-828,120
| -66% | -$9.4M | ﹤0.01% | 2928 |
|
|
2017
Q3 | $18.1M | Buy |
1,250,297
+1,150,934
| +1,158% | +$15.7M | 0.01% | 1136 |
|
|
2017
Q2 | $1.2M | Buy |
+99,363
| New | +$1.38M | ﹤0.01% | 3826 |
|
|
2017
Q1 | – | Sell |
-11,304
| Closed | -$132K | – | 7515 |
|
|
2016
Q4 | $137K | Sell |
11,304
-29,742
| -72% | -$316K | ﹤0.01% | 6548 |
|
|
2016
Q3 | $377K | Buy |
+41,046
| New | +$429K | ﹤0.01% | 5299 |
|
|
2016
Q2 | – | Sell |
-14,551
| Closed | -$119K | – | 6901 |
|
|
2016
Q1 | $103K | Buy |
14,551
+9,576
| +192% | +$70K | ﹤0.01% | 6011 |
|
|
2015
Q4 | $52K | Sell |
4,975
-16,388
| -77% | -$161K | ﹤0.01% | 7278 |
|
|
2015
Q3 | $143K | Buy |
21,363
+2,016
| +10% | +$13.8K | ﹤0.01% | 6556 |
|
|
2015
Q2 | $130K | Sell |
19,347
-162,015
| -89% | -$1.06M | ﹤0.01% | 6813 |
|
|
2015
Q1 | $1.23M | Buy |
181,362
+62,898
| +53% | +$470K | ﹤0.01% | 3665 |
|
|
2014
Q4 | $949K | Buy |
118,464
+32,366
| +38% | +$139K | ﹤0.01% | 3832 |
|
|
2014
Q3 | $303K | Buy |
86,098
+62,843
| +270% | +$264K | ﹤0.01% | 5248 |
|
|
2014
Q2 | $111K | Sell |
23,255
-121,119
| -84% | -$739K | ﹤0.01% | 6151 |
|
|
2014
Q1 | $1.37M | Buy |
+144,374
| New | +$1.31M | ﹤0.01% | 3030 |
|
Other funds holding CYTK
VPM
VCM
ACA
Ken Griffin's CYTK Position: Q1 2026 in Review
Ken Griffin reduced its Cytokinetics (CYTK) stake by 5.4% in Q1 2026, selling an estimated $4.01M and leaving 1,099,858 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #1052.
Ken Griffin first reported a position in CYTK in Q1 2014 and has held it in 45 quarters since. The position peaked at $182M in Q2 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Ken Griffin held 1,099,858 shares of Cytokinetics worth $72.5M as of Q1 2026.
- Ken Griffin sold 63,079 Cytokinetics shares in Q1 2026, an estimated $4.01M.
- Cytokinetics made up 0.01% of Ken Griffin's portfolio in Q1 2026, its #1052 holding.
- Ken Griffin first reported a position in Cytokinetics in Q1 2014 and has held it in 45 quarters since.
- Ken Griffin's Cytokinetics position peaked at $182M in Q2 2022.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.